Panel

Irman Forghani, MD

Clinical Assistant Professor
Division of Clinical and Translational Genetics
University of Miami

Dana Chase, MD, FACOG

Associate Professor
Creighton University
University of Arizona College of Medicine
Gynecologic Oncologist, Arizona Oncology

Thomas J. Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

Brian Slomovitz, MD

Professor, Florida International University
Gynecologic Oncology, Broward Health

In this month's journal scan, our panel reviews:

1. Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
2. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
3. Randomized Phase II Placebo-Controlled Trial with Farletuzumab (FAR) or Placebo Plus Carboplatin/Paclitaxel or Carboplatin/Pegylated Liposomal Doxorubicin in Low CA-125 Platinum-Sensitive Ovarian Cancer
4. Efficacy of niraparib by timing of surgery and residual disease: a post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Panel

Srdan Verstovsek, MD, PhD

Professor of Medicine
Department of Leukemia
Division of Cancer Medicine
MD Anderson

Prithviraj Bose, MD

Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson

In this month's journal scan, our panel reviews:

1. Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms
2. A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
3. The COVID-19 Pandemic – Myeloproliferative Neoplasms and Jakafi (ruxolitinib)

Panel

Sara Tolaney, MD, MPH

Associate Director, Susan F. Smith Center for Women’s Cancers
Director, Clinical Trials, Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School

Bhuvaneswari Ramaswamy, MD, MRCP

Professor and Section Chief- Breast Medical Oncology
The Ohio State University Comprehensive Cancer Center

In this month's journal scan, our panel reviews:

1. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
2. Biomarker Evaluation in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer
3. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)

Panel

Brian Slomovitz, MD

Professor, Florida International University
Gynecologic Oncology, Broward Health

BJ Rimel, MD

Assistant Professor
Obstetrics and Gynecology
Cedars-Sinai Medical Center

In this month's journal scan, our panel reviews:

1. MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer
2. Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
3. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)

Panel

THOMAS J. HERZOG, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

DANA CHASE, MD, FACOG

Associate Professor
Creighton University
University of Arizona College of Medicine
Gynecologic Oncologist, Arizona Oncology

BRIAN SLOMOVITZ, MD

Professor, Florida International University
Gynecologic Oncology, Broward Health

In this month's journal scan our panel reviews:

1. Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer
2. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study
3. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC

Panel

Krishnansu Tewari, MD

Professor, Division of Gynecologic Oncology
The Philip J. DiSaia, MD Chair in Gynecologic Oncology, Obstetrics & Gynecology
School of Medicine
University of California, Irvine

Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

Dana Chase, MD, FACOG

Associate Professor
Creighton University
University of Arizona College of Medicine
Gynecologic Oncologist, Arizona Oncology

In this month's journal scan, our panel reviews:

1. Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer
2. Efficacy and Safety of Niraparib in Older Patients With Advanced Ovarian Cancer: Results From the PRIMA/ENGOT-OV26/GOG-3012 Trial
3. Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016

Panel

Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

Thomas Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

Dana Chase, MD, FACOG

Associate Professor
Creighton University
University of Arizona College of Medicine
Gynecologic Oncologist, Arizona Oncology

In this month's journal scan, our panel reviews:

1. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
2. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
3. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect

Panel

Dana Chase, MD, FACOG

Associate Professor
Creighton University
University of Arizona College of Medicine
Gynecologic Oncologist, Arizona Oncology

Thomas Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

In this ovarian cancer journal scan, our panel reviews:

1) BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

2) Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

3) Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

Panel

BJ Rimel, MD

Assistant Professor
Obstetrics and Gynecology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

Thomas Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

In this ovarian cancer journal scan, our panel reviews:

1) The results of the randomised phase III GOG-0213 study that involved patients with platinum-sensitive, recurrent epithelial ovarian cancer, secondary surgical cytoreduction followed by chemotherapy.

2) The Food and Drug Administration approval of niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.

3) The randomized Phase II Trial of Nivolumab vs. Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.